Loading, please wait ...


News Analytics

7dcbab00b0cd29dbb7275063f075010d5f8b2419 1200x1200 jpg?fit=crop&auto=format.
These data were presented previously at the virtual 2020 ESMO Congress.2 “The single-agent activity of cosibelimab in NSCLC is compelling, with the observed 44.0% objective response rate and 10.3-month median progression-free survival comparing favorably to the datasets generated in similar subjects from the PD-(L)1 therapies available today,” said James F. Oliviero, president and chief executive officer of Checkpoint Therapeutics, Inc., the ...

Subject Matter

  • Healthcare 76.06%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 23.94%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions